Featuring perspectives from Dr Paul G Richardson, including the following topics:

• EXCALIBER-RRMM: A Phase III trial of iberdomide, daratumumab and dexamethasone for relapsed/refractory multiple myeloma (0:00)
  • Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract
• Phase III SUCCESSOR-1 and SUCCESSOR-2 studies evaluating mezigdomide-based regimens for relapsed/refractory multiple myeloma (8:24)
  • Richardson PG et al. A phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1. SOHO 2023;Abstract MM-372.
  • Richardson PG et al. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. ASCO 2023;Abstract TPS8070.
• EMN26: A Phase II study of maintenance therapy with iberdomide after autologous stem-cell transplantation for newly diagnosed multiple myeloma (13:34)
  • van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. ASH 2025;Abstract 101.
• STOMP: A Phase I study of selinexor, mezigdomide and dexamethasone for patients with relapsed/refractory multiple myeloma who experienced relapse with or are ineligible for T-cell-redirecting therapy (24:53)
  • Mo C et al. Selinexor, mezigdomide, and dexamethasone in patients with relapsed/refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results. ASH 2025;Abstract 4010.

CME information and select publications

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics:

• Gastroesophageal cancer (0:00)
• Recurrent colorectal cancer (5:43)
• Colorectal cancer with brain metastases (9:59)

CME information and select publications

Featuring an interview with Dr Ravin Ratan, including the following topics:

• Case: A woman in her early 40s who develops intense nausea and vomiting and is diagnosed with a pelvic desmoid tumor elects surveillance and experiences spontaneous regression of the tumor (0:00)
• Case: A woman in her late 30s with a painful desmoid tumor in the right pelvic wall receives cryoablation because of concerns about ovarian function (6:49)
• Case: A woman in her early 40s with breast implants and multiple resections of breast desmoid tumors receives nirogacestat for 2 years with positive response but develops mucositis and Grade 1 asthenia and stops treatment (14:10)
• Case: A woman in her mid 30s with a history of gastric sleeve and endometriosis presents with a painful desmoid tumor in the left upper quadrant, receives nirogacestat with headaches and gastrointestinal symptoms that improve over time and experiences a decrease in tumor size (21:27)

CME information and select publications

Featuring perspectives from Dr Jaffer A Ajani, Dr Samuel J Klempner, Dr Rutika Mehta and Dr John Strickler, moderated by Dr Klempner, including the following topics:

• Older patient with metastatic claudin 18.2-positive gastroesophageal (GE) cancer (0:00)
• Management of nausea and vomiting with zolbetuximab for GE cancer (9:37)
• Younger patient with metastatic claudin 18.2-positive, PD-L1-positive GE cancer (15:34)

CME information and select publications

Featuring slide presentations and related discussion from Dr Nikhil I Khushalani, Dr Soo J Park, Dr Vishal Anil Patel and Dr Evan Wuthrick, including the following topics:

• Introduction (0:00)
• Current Management of Localized, Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) (9:55)
• Case: A man in his early 70s with cSCC who previously underwent surgery and adjuvant therapy (32:39)
• Case: A man in his early 60s with cSCC who receives cemiplimab (54:45)
• Incorporation of Radiation Therapy into the Multidisciplinary Management of cSCC and Basal Cell Carcinoma (BCC) (1:04:24)
• Case: A man in his early 70s with cSCC who receives radiation therapy after a surgeon expresses concern about the risks of surgery (1:22:15)
• Case: A man in his late 80s with cSCC who is not a candidate for surgery (1:24:09)
• Evidence-Based Treatment Strategies for Patients with BCC (1:26:00)
• Case: A man in his mid sixties with BCC who receives sonidegib (1:36:49)
• Case: A man in his late 70s with BCC who receives vismodegib (1:38:32)
• Dermatologic Care for Patients with cSCC and BCC (1:45:09)

CME information and select publications

Featuring an interview with Dr Hanny Al-Samkari, including the following topics:

• Case: A man in his early 40s with chronic immune thrombocytopenia (ITP) receives romiplostim with rituximab — Bhavana (Tina) Bhatnagar, DO (0:00)
• Case: A woman in her early 80s with metastatic adenocarcinoma of the lung responds to carboplatin/pemetrexed/pembrolizumab but after 14 months of maintenance pembrolizumab presents with ITP — Susmitha Apuri, MD (6:48)
• Case: A man in his late 70s with a 30-year history of chronic ITP who received corticosteroids and rituximab now receives avatrombopag — Sunil Gandhi, MD (12:06)
• Case: A woman in her early 80s with multiple comorbidities and a long history of ITP presents with confusion and fluid retention due to exacerbated congestive heart failure and receives fostamatinib — Dr Bhatnagar (19:26)

CME information and select publications

Featuring perspectives from Prof Karim Fizazi and Dr Daniel George, moderated by Dr Elisabeth I Heath, including the following topics:

• Introduction (0:00)
• Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr George (3:25)
• Targeting AKT in Metastatic Prostate Cancer — Prof Fizazi (32:54)
• Tolerability and Other Practical Considerations with Capivasertib — Dr Heath (1:03:15)

CME information and select publications

Featuring perspectives from Ms Jamie Carroll, Prof Giuseppe Curigliano, Dr Marie E McDonnell and Dr Hope S Rugo, including the following topics:

• Introduction: Use of On-Body Glucose Monitoring Devices (0:00)
• Overview of Breast Cancer and Diabetes (9:39)
• PI3K/AKT/mTOR Pathway and Glucose Metabolism (19:28)
• Case Presentations — Part 1 (26:02)
• Current Data with Alpelisib, Capivasertib and Inavolisib (43:51)
• Prevention and Management of Hyperglycemia (1:02:17)
• Case Presentations — Part 2 (1:10:24)

CME information and select publications